| Literature DB >> 27456825 |
Gholamreza Azizi, Hassan Abolhassani, Mohammad Hosein Asgardoon, Javad Rahnavard, Majid Zaki Dizaji, Reza Yazdani, Javad Mohammadi, Asghar Aghamohammadi1.
Abstract
Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Immunoglobulin; infection; primary antibody deficiency; primary immunodeficiency diseases
Year: 2016 PMID: 27456825 DOI: 10.2174/1871530316666160724214418
Source DB: PubMed Journal: Endocr Metab Immune Disord Drug Targets ISSN: 1871-5303 Impact factor: 2.895